Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7473.091 | 2.2915 | 1.8550 | 2.3297 | |
| Hs 578T | TNBC | Basal B | Nutlin 3a | MDM2 | MDM2 | 0.00427 | uM | 7473.066 | 2.3046 | 1.8496 | 2.3582 | |
| Hs 578T | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7861.018 | 2.3084 | 4.3604 | 0.8485 | |
| Hs 578T | TNBC | Basal B | GSK1838705A | IGF1R | RTK | 2.67 | uM | 7472.092 | 2.3185 | 2.8827 | 1.2676 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7472.092 | 2.3318 | 2.9002 | 1.2676 | |
| Hs 578T | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 16.7 | uM | 7473.098 | 2.3320 | 1.8990 | 2.2810 | |
| LY2 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7477.084 | 2.3377 | 3.9001 | 0.9476 | |
| Hs 578T | TNBC | Basal B | PS-1145 | IKK | NFKB | 1890 | uM | 7472.065 | 2.3456 | 3.7607 | 0.9830 | |
| LY2 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7477.084 | 2.3777 | 3.9886 | 0.9476 | |
| Hs 578T | TNBC | Basal B | TPCA-1 | IKK | NFKB | 5.33 | uM | 7472.1 | 2.4009 | 3.3965 | 1.1120 | |
| Hs 578T | TNBC | Basal B | PS-1145 | IKK | NFKB | 0.606 | uM | 7472.065 | 2.4113 | 3.8964 | 0.9830 | |
| Hs 578T | TNBC | Basal B | Trichostatin A | HDAC | HDAC | 1.6 | uM | 7472.065 | 2.4302 | 3.9355 | 0.9830 | |
| MCF 10F | NM | - | Doxorubicin | TOP2 | TOP | 86.2 | uM | 7872.007 | 2.4960 | 2.4119 | 1.7126 | |
| Hs 578T | TNBC | Basal B | GSK1838705A | IGF1R | RTK | 0.0213 | uM | 7472.098 | 2.4965 | 2.6661 | 1.5098 | |
| HCC1806 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 13.3 | uM | 7450.091 | 2.5440 | 3.9004 | 1.0419 | |
| HCC1806 | TNBC | Basal A | GSK1838705A | IGF1R | RTK | 0.213 | uM | 7450.091 | 2.5477 | 3.9072 | 1.0419 | |
| HCC1806 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7450.091 | 2.5884 | 3.9824 | 1.0419 | |
| HCC1806 | TNBC | Basal A | GSK1838705A | IGF1R | RTK | 0.00853 | uM | 7450.091 | 2.6455 | 4.0878 | 1.0419 | |
| HCC1806 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 0.107 | uM | 7450.091 | 2.6469 | 4.0904 | 1.0419 | |
| HCC1806 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7450.091 | 2.6511 | 4.0983 | 1.0419 | |
| HCC1806 | TNBC | Basal A | GSK1838705A | IGF1R | RTK | 0.000341 | uM | 7450.091 | 2.6811 | 4.1536 | 1.0419 | |
| HCC1806 | TNBC | Basal A | GSK1838705A | IGF1R | RTK | 0.00171 | uM | 7450.091 | 2.7399 | 4.2620 | 1.0419 | |
| HCC1806 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7450.091 | 2.7501 | 4.2808 | 1.0419 | |
| HCC1806 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7450.091 | 2.7625 | 4.3037 | 1.0419 | |
| HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7450.091 | 2.7673 | 4.3125 | 1.0419 |